Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Ethanol enhances arsenic-induced cyclooxygenase-2 expression via both NFAT and NF-κB signalings in colorectal cancer cells.

Lei Wang | John Andrew Hitron | James T F Wise | Young-Ok Son | Ram Vinod Roy | Donghern Kim | Jin Dai | Poyil Pratheeshkumar | Zhuo Zhang | Mei Xu | Jia Luo | Xianglin Shi
Toxicology and applied pharmacology | 2015

Arsenic is a known carcinogen to humans, and chronic exposure to environmental arsenic is a worldwide health concern. As a dietary factor, ethanol carries a well-established risk for malignancies, but the effects of co-exposure to arsenic and ethanol on tumor development are not well understood. In the present study, we hypothesized that ethanol would enhance the function of an environmental carcinogen such as arsenic through increase in COX-2 expression. Our in vitro results show that ethanol enhanced arsenic-induced COX-2 expression. We also show that the increased COX-2 expression associates with intracellular ROS generation, up-regulated AKT signaling, with activation of both NFAT and NF-κB pathways. We demonstrate that antioxidant enzymes have an inhibitory effect on arsenic/ethanol-induced COX-2 expression, indicating that the responsive signaling pathways from co-exposure to arsenic and ethanol relate to ROS generation. In vivo results also show that co-exposure to arsenic and ethanol increased COX-2 expression in mice. We conclude that ethanol enhances arsenic-induced COX-2 expression in colorectal cancer cells via both the NFAT and NF-κB pathways. These results imply that, as a common dietary factor, ethanol ingestion may be a compounding risk factor for arsenic-induced carcinogenesis/cancer development.

Pubmed ID: 26220687

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIEHS NIH HHS, United States
    Id: R01ES020870
  • Agency: NCI NIH HHS, United States
    Id: R01 CA119028
  • Agency: NIEHS NIH HHS, United States
    Id: R01ES021771
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES020870
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES025515
  • Agency: NCI NIH HHS, United States
    Id: R01 CA116697
  • Agency: NIEHS NIH HHS, United States
    Id: R01ES017244
  • Agency: NIEHS NIH HHS, United States
    Id: T32 ES007266
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES021771
  • Agency: NCI NIH HHS, United States
    Id: P30 CA177558
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES017244
  • Agency: NIEHS NIH HHS, United States
    Id: R01ES025515

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


RayBiotech (tool)

RRID:SCR_005517

An Antibody supplier

View all literature mentions